Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
Regeneron Pharmaceuticals (NASDAQ: REGN) will announce its fourth quarter and full year 2020 financial results on February 5, 2021, before U.S. markets open. A conference call will occur at 8:30 AM ET the same day, accessible by dialing (888) 660-6127 for U.S. callers or (973) 890-8355 for international participants, using conference ID 1580376. A webcast link will be available on their Investors and Media page. Regeneron is renowned for its innovations in biotechnology, focusing on treatments for serious diseases.
- None.
- None.
TARRYTOWN, N.Y., Jan. 19, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Friday, February 5, 2021, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International), conference ID 1580376. A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com
Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2020-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-5-2021-301211100.html
SOURCE Regeneron Pharmaceuticals, Inc.
FAQ
When will Regeneron report its fourth quarter and full year 2020 results?
What time is the Regeneron conference call scheduled for?
How can I access the Regeneron conference call?
Where can I find the webcast for Regeneron's conference call?
What is Regeneron known for?
